Evidence map›Paper›PMID 40978151›Full record

ArticleiScience2025

Exosomes derived from 3D-cultured hUCMSCs exhibit superior hepatoprotection against ALF.

Huixin Tang, Wang Lu, Qi Yang, Yizhi Zhang, Xiaoxuan Liu, Shanshan Li, Manman Xu, Zhongping Duan, Li Bai, Yu Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huixin TangFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Wang LuFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Qi YangFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Yizhi ZhangDepartment of Critical Liver Diseases, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Xiaoxuan LiuFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Shanshan LiFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Manman XuFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zhongping DuanFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Li BaiFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Yu ChenFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most recently, exosomes (Exos) derived from 3D-cultured cells exhibit great advantages over 2D-Exos. Nevertheless, it remains to be explored whether 3D (tissue engineering liver) exosomes are superior to 2D-Exos in protecting mice from acute liver injury (ALF) and the underlying mechanism. Herein, we demonstrated that 3D-Exos manifested higher yields, protein concentration and RNA content compared to 2D-Exos. Remarkably, 3D-Exos exhibited superior hepatoprotection against ALF, as shown by reduced TBiL levels, improved liver architecture and alleviated inflammation. According to miRNA sequencing and KEGG enrichment analysis, the differentially expressed genes between 2D- and 3D-Exos could be enriched in "Hippo-YAP" and "autophagy" pathways. Moreover, the levels of YAP/TAZ and autophagy markers were more elevated in 3D-Exos-treated mice. Specifically, inhibiting YAP and autophagy signaling destroyed the hepatoprotection conferred by 3D-Exos. Collectively, 3D-Exos exert superior hepatoprotection against ALF by up-regulating YAP and autophagy signaling. Our finding provides powerful support for administering 3D-Exos to treat ALF efficiently.

Indexed as

BiochemistryCell biologyTissue Engineering

Identifiers

PMID40978151
PMCPMC12446390

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.